Neoamlessini (Amlodipine, Perindopril Arginine)

Amlodipine blocks L‑type calcium channels in arterial smooth muscle, causing vasodilation and reduced peripheral resistance. Perindopril arginine inhibits the angiotensin‑converting enzyme, decreasing formation of angiotensin II and aldosterone, which also promotes vasodilation and reduces fluid retention. Together they produce a synergistic antihypertensive effect.

The appropriate dose of Neoamlessini is determined by the prescribing healthcare professional based on the patient’s blood pressure, renal function, and overall clinical profile. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety of Neoamlessini during pregnancy or lactation has not been fully established. It should be avoided unless the potential benefit outweighs the risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To request Neoamlessini, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy agents, Neoamlessini offers the convenience of a single tablet that combines a calcium‑channel blocker and an ACE inhibitor. This dual action can achieve better blood pressure control, reduce pill burden, and may improve adherence versus taking two separate medications.

Neoamlessini should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Neoamlessini is taken orally, usually once daily. The tablet should be swallowed whole with a glass of water and may be taken with or without food. Patients should not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious adverse events include angioedema (swelling of the face, lips, tongue, or throat), severe hypotension (marked dizziness or fainting), and significant liver enzyme elevation. If any of these occur, patients should seek immediate medical attention and discontinue the medication as directed by their clinician.

Neoamlessini is contraindicated in individuals with known hypersensitivity to amlodipine, perindopril, or any component of the formulation. It should also be avoided in patients with a history of ACE‑inhibitor‑induced angioedema, severe renal impairment, or in women who are pregnant unless the benefit justifies the risk.